DK3274455T3 - Oligonucleotidsekvenser, som er målrettede transkriptionsfaktor TSC22D4 til behandling af insulinresistens - Google Patents
Oligonucleotidsekvenser, som er målrettede transkriptionsfaktor TSC22D4 til behandling af insulinresistens Download PDFInfo
- Publication number
- DK3274455T3 DK3274455T3 DK16704222.5T DK16704222T DK3274455T3 DK 3274455 T3 DK3274455 T3 DK 3274455T3 DK 16704222 T DK16704222 T DK 16704222T DK 3274455 T3 DK3274455 T3 DK 3274455T3
- Authority
- DK
- Denmark
- Prior art keywords
- tsc22d4
- treatment
- transcription factor
- insulin resistance
- oligonucleotide sequences
- Prior art date
Links
- 101000640735 Homo sapiens TSC22 domain family protein 4 Proteins 0.000 title 1
- 206010022489 Insulin Resistance Diseases 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15160259.6A EP3072969A1 (en) | 2015-03-23 | 2015-03-23 | Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance |
| PCT/EP2016/053050 WO2016150618A1 (en) | 2015-03-23 | 2016-02-12 | Oligonucleotide sequences targeting transcription factor tsc22d4 for the treatment of insulin resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3274455T3 true DK3274455T3 (da) | 2020-12-14 |
Family
ID=52784935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16704222.5T DK3274455T3 (da) | 2015-03-23 | 2016-02-12 | Oligonucleotidsekvenser, som er målrettede transkriptionsfaktor TSC22D4 til behandling af insulinresistens |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10676739B2 (enExample) |
| EP (2) | EP3072969A1 (enExample) |
| JP (1) | JP2018513841A (enExample) |
| KR (1) | KR20170128348A (enExample) |
| CN (1) | CN107278229A (enExample) |
| BR (1) | BR112017016021A2 (enExample) |
| CA (1) | CA2979115A1 (enExample) |
| DK (1) | DK3274455T3 (enExample) |
| ES (1) | ES2837085T3 (enExample) |
| MX (1) | MX384193B (enExample) |
| RU (1) | RU2723091C2 (enExample) |
| WO (1) | WO2016150618A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7289510B2 (ja) * | 2019-05-08 | 2023-06-12 | 国立大学法人高知大学 | 認知症治療薬のスクリーニング方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1206234A4 (en) * | 1999-06-03 | 2005-06-01 | Jessie L S Au | METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| JP4869942B2 (ja) | 2003-12-11 | 2012-02-08 | ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド | インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４ |
| AU2005248147A1 (en) * | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| US7943306B2 (en) * | 2005-01-12 | 2011-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Gene expression signature for prediction of human cancer progression |
| US20140227289A1 (en) | 2011-05-13 | 2014-08-14 | Stephen Michael Cohen | Compounds and methods for treating insulin resistance syndrome |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| EP2816356A1 (en) | 2013-06-17 | 2014-12-24 | Ruprecht-Karls-Universität Heidelberg | Treatment of insulin resistance through inhibitors of transcription factor TSC22D4 |
| RU2573450C1 (ru) * | 2014-08-11 | 2016-01-20 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Способ выявления генов-мишеней для диагностики и терапии лейкозов человека |
-
2015
- 2015-03-23 EP EP15160259.6A patent/EP3072969A1/en not_active Withdrawn
-
2016
- 2016-02-12 CN CN201680012500.4A patent/CN107278229A/zh active Pending
- 2016-02-12 RU RU2017131900A patent/RU2723091C2/ru active
- 2016-02-12 CA CA2979115A patent/CA2979115A1/en active Pending
- 2016-02-12 EP EP16704222.5A patent/EP3274455B1/en active Active
- 2016-02-12 WO PCT/EP2016/053050 patent/WO2016150618A1/en not_active Ceased
- 2016-02-12 JP JP2017546667A patent/JP2018513841A/ja active Pending
- 2016-02-12 ES ES16704222T patent/ES2837085T3/es active Active
- 2016-02-12 US US15/545,104 patent/US10676739B2/en active Active
- 2016-02-12 BR BR112017016021-8A patent/BR112017016021A2/pt not_active IP Right Cessation
- 2016-02-12 KR KR1020177026584A patent/KR20170128348A/ko not_active Ceased
- 2016-02-12 DK DK16704222.5T patent/DK3274455T3/da active
- 2016-02-12 MX MX2017012231A patent/MX384193B/es unknown
-
2020
- 2020-04-30 US US16/862,930 patent/US11053499B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3274455B1 (en) | 2020-10-14 |
| BR112017016021A2 (pt) | 2018-03-20 |
| CA2979115A1 (en) | 2016-09-29 |
| RU2017131900A3 (enExample) | 2019-06-10 |
| WO2016150618A1 (en) | 2016-09-29 |
| KR20170128348A (ko) | 2017-11-22 |
| JP2018513841A (ja) | 2018-05-31 |
| EP3072969A1 (en) | 2016-09-28 |
| US10676739B2 (en) | 2020-06-09 |
| US20180023078A1 (en) | 2018-01-25 |
| CN107278229A (zh) | 2017-10-20 |
| ES2837085T3 (es) | 2021-06-29 |
| MX384193B (es) | 2025-03-12 |
| RU2723091C2 (ru) | 2020-06-08 |
| RU2017131900A (ru) | 2019-04-23 |
| US20200255834A1 (en) | 2020-08-13 |
| US11053499B2 (en) | 2021-07-06 |
| EP3274455A1 (en) | 2018-01-31 |
| MX2017012231A (es) | 2018-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3445850T3 (da) | Fremgangsmåder til tilvejebringelse af enkeltstrenget rna | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3636764T3 (da) | 3'-utr-sekvenser til rna-stabilisering | |
| EP3314027A4 (en) | THERAPEUTIC OLIGONUCLEOTIDES | |
| EP3328873A4 (en) | TARGETED OLIGONUCLEOTIDES | |
| DK3580211T3 (da) | 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer | |
| DK3436589T3 (da) | Ny minimale utr-sekvenser | |
| IL250016B (en) | Antisense oligonucleotides for the treatment of usher syndrome type 2 | |
| LT3119437T (lt) | Genų terapija, skirta pigmentiniam retinitui | |
| EP3307889A4 (en) | DEFINED MULTICONJUGATE OLIGONUCLEOTIDES | |
| DK3322722T3 (da) | Midler, anvendelser og fremgangsmåder til behandling af synukleinopati | |
| DK3167059T3 (da) | Stabilisering af poly(a)-sekvens, der koder for dna-sekvenser | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3366295T3 (da) | Fremgangsmåder til behandling af filoviridae virusinfektioner | |
| HUE054784T2 (hu) | 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók | |
| DK3262066T4 (da) | Genterapi | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3374359T3 (da) | Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer | |
| DK3145947T3 (da) | Rekombinante mikroorganismer, som er i stand til fiksering af kulstof | |
| DK3307296T3 (da) | Timp2 til anvendelse til behandling af aldringsassocierede tilstande | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3294283T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens | |
| DK3155017T3 (da) | Forbedrede lægemidler til insulinresistens | |
| DK3193978T3 (da) | Lægemiddelinjektor af hudplastertypen til voluminøs bolus med medikamentforvarmning | |
| DK3373980T3 (da) | Fremgangsmåder til behandling af muskeldystrofi |